259 related articles for article (PubMed ID: 14969621)
1. Incidence and time course of thrombocytopenia with abciximab and eptifibatide in patients undergoing percutaneous coronary intervention.
Fahdi IE; Saucedo JF; Hennebry T; Ghani M; Sadanandan S; Garza-Arreola L
Am J Cardiol; 2004 Feb; 93(4):453-5. PubMed ID: 14969621
[TBL] [Abstract][Full Text] [Related]
2. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, eptifibatide and abciximab: outcomes, complications and thrombocytopenia during percutaneous coronary intervention.
Suleiman M; Gruberg L; Hammerman H; Aronson D; Halabi M; Goldberg A; Grenadier E; Boulus M; Markiewicz W; Beyar R
J Invasive Cardiol; 2003 Jun; 15(6):319-23. PubMed ID: 12777670
[TBL] [Abstract][Full Text] [Related]
3. Acute profound thrombocytopenia following abciximab therapy.
Bishara AI; Hagmeyer KO
Ann Pharmacother; 2000; 34(7-8):924-30. PubMed ID: 10928405
[TBL] [Abstract][Full Text] [Related]
4. The relative safety and efficacy of abciximab and eptifibatide in patients undergoing primary percutaneous coronary intervention: insights from a large regional registry of contemporary percutaneous coronary intervention.
Gurm HS; Smith DE; Collins JS; Share D; Riba A; Carter AJ; LaLonde T; Kline-Rogers E; O'Donnell M; Changezi H; Zughaib M; Safian R; Moscucci M;
J Am Coll Cardiol; 2008 Feb; 51(5):529-35. PubMed ID: 18237680
[TBL] [Abstract][Full Text] [Related]
5. Platelet receptor glycoprotein IIb/IIIa inhibition with eptifibatide in a patient with thrombocytopenia after treatment with abciximab.
Coto H
J Invasive Cardiol; 2000 Oct; 12(10):528-31. PubMed ID: 11022214
[TBL] [Abstract][Full Text] [Related]
6. Thrombocytopenia associated with c7E3 Fab (abciximab).
Schell DA; Ganti AK; Levitt R; Potti A
Ann Hematol; 2002 Feb; 81(2):76-9. PubMed ID: 11907786
[TBL] [Abstract][Full Text] [Related]
7. Thrombocytopenia complicating treatment with intravenous glycoprotein IIb/IIIa receptor inhibitors: a pooled analysis.
Dasgupta H; Blankenship JC; Wood GC; Frey CM; Demko SL; Menapace FJ
Am Heart J; 2000 Aug; 140(2):206-11. PubMed ID: 10925331
[TBL] [Abstract][Full Text] [Related]
8. Monitoring platelet function in glycoprotein IIB/IIIA inhibitor therapy.
Wu KK; Willerson JT
Circulation; 2001 May; 103(21):2528-30. PubMed ID: 11382717
[No Abstract] [Full Text] [Related]
9. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting.
Merlini PA; Rossi M; Menozzi A; Buratti S; Brennan DM; Moliterno DJ; Topol EJ; Ardissino D
Circulation; 2004 May; 109(18):2203-6. PubMed ID: 15117843
[TBL] [Abstract][Full Text] [Related]
10. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
Topol EJ; Moliterno DJ; Herrmann HC; Powers ER; Grines CL; Cohen DJ; Cohen EA; Bertrand M; Neumann FJ; Stone GW; DiBattiste PM; Demopoulos L;
N Engl J Med; 2001 Jun; 344(25):1888-94. PubMed ID: 11419425
[TBL] [Abstract][Full Text] [Related]
11. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
Gawaz M; Ruf A; Neumann FJ; Pogátsa-Murray G; Dickfeld T; Zohlnhöfer D; Schömig A
Thromb Haemost; 1998 Dec; 80(6):994-1001. PubMed ID: 9869173
[TBL] [Abstract][Full Text] [Related]
12. Platelet activation as a potential mechanism of GP IIb/IIIa inhibitor-induced thrombocytopenia.
Peter K; Straub A; Kohler B; Volkmann M; Schwarz M; Kübler W; Bode C
Am J Cardiol; 1999 Sep; 84(5):519-24. PubMed ID: 10482148
[TBL] [Abstract][Full Text] [Related]
13. Time course, magnitude, and consistency of platelet inhibition by abciximab, tirofiban, or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention.
Kereiakes DJ; Broderick TM; Roth EM; Whang D; Shimshak T; Runyon JP; Hattemer C; Schneider J; Lacock P; Mueller M; Abbottsmith CW
Am J Cardiol; 1999 Aug; 84(4):391-5. PubMed ID: 10468074
[TBL] [Abstract][Full Text] [Related]
14. Emergency coronary artery bypass surgery in the era of glycoprotein IIb/IIIa receptor antagonist use.
Pang JT; Fort S; Della Siega A; Cohen EA
J Card Surg; 2002; 17(5):425-31. PubMed ID: 12630543
[TBL] [Abstract][Full Text] [Related]
15. Abciximab-associated thrombocytopenia after previous tirofiban-related thrombocytopenia.
Dorsch MP; Montague D; Rodgers JE; Patterson C
Pharmacotherapy; 2006 Mar; 26(3):423-7. PubMed ID: 16503724
[TBL] [Abstract][Full Text] [Related]
16. Determination of platelet aggregation inhibition during percutaneous coronary intervention with the platelet function analyzer PFA-100.
Madan M; Berkowitz SD; Christie DJ; Smit AC; Sigmon KN; Tcheng JE
Am Heart J; 2002 Jul; 144(1):151-8. PubMed ID: 12094202
[TBL] [Abstract][Full Text] [Related]
17. Thrombocytopenia and glycoprotein IIb-IIIa receptor antagonists.
Stiegler HM; Fischer Y; Steiner S
Lancet; 1999 Apr; 353(9159):1185. PubMed ID: 10210005
[No Abstract] [Full Text] [Related]
18. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study.
Steinhubl SR; Talley JD; Braden GA; Tcheng JE; Casterella PJ; Moliterno DJ; Navetta FI; Berger PB; Popma JJ; Dangas G; Gallo R; Sane DC; Saucedo JF; Jia G; Lincoff AM; Theroux P; Holmes DR; Teirstein PS; Kereiakes DJ
Circulation; 2001 May; 103(21):2572-8. PubMed ID: 11382726
[TBL] [Abstract][Full Text] [Related]
19. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel.
Kastrati A; Mehilli J; Schühlen H; Dirschinger J; Dotzer F; ten Berg JM; Neumann FJ; Bollwein H; Volmer C; Gawaz M; Berger PB; Schömig A;
N Engl J Med; 2004 Jan; 350(3):232-8. PubMed ID: 14724302
[TBL] [Abstract][Full Text] [Related]
20. Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy.
Sane DC; Damaraju LV; Topol EJ; Cabot CF; Mascelli MA; Harrington RA; Simoons ML; Califf RM
J Am Coll Cardiol; 2000 Jul; 36(1):75-83. PubMed ID: 10898416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]